Doc:20210407-sg12-b19.redacted
[ 1 ]TF [mg/dL]
TFS
MCV
GOT
GFR
87
100
200
31%
82
20
115
Treatment
FT [µg/L]
Q4 '17
Fe [µg/dL]
S 12 KR 1268/20, S 12 KR 2059/20, B19
pre
Q1 '18
82
20-70
115
Ctx, OP
Q2 '18
83
22-29
110
Ctx
86
29-47
120
Ctx, RT, OMT
Q3 '18
2300
200
Q4 '18
88-97
OMT
Q1 '19
OMT
Q2 '19
101
Q3 '19 Q4 '19
46 202
182
79%
112
106
OMT
99
OMT
94
OMT
Q1 '20
OMT
Q2 '20
2400
182
106
Q3 '20
137
2000
170
58%
Q4 '20
162
1400-2100
112-172
67%
Q1 '21
123-194
1100-1200
182
50-76%
47
91
37
105 73-92
104
50
89-96
OMT Sep